Optimized PEGylated cubosomes: a novel approach for specific delivery of dacomitinib to non-small cell lung cancer cells
Mohamed Nasr, Rania Mokhtar, Rania S. Abdel-Rashid
Abstract
Dacomitinib (DM), a newly FDA-approved chemotherapeutic agent, demonstrates remarkable selectivity in combating non-small cell lung cancer (NSCLC) and hindering its severe metastasis.
Topics & Concepts
Lung cancerPharmacologyPEGylationMedicineOncologyPEG ratioBusinessFinancePeptidase Inhibition and AnalysisLung Cancer Research Studies